Regarding B3GALNT2, it has been found upregulated at both mRNA (from 1.08- to 2.85-fold) and protein (from 1.51- till 2.97-fold) levels in all hepatocellular carcinoma cell lines analyzed, with the sole exception of BEL-7405, where a reduced expression (by ‒2.56-fold) of B3GALNT2 was observed at the mRNA, but not at the protein level [117]. This evidence concerns the gene B3GALNT2 and hepatocellular carcinoma.